Literature DB >> 15513358

Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry.

R Ehehalt1, J Wagenblast, G Erben, W D Lehmann, U Hinz, U Merle, W Stremmel.   

Abstract

BACKGROUND: A defective mucus composition represents a key pathogenetic factor for intestinal injury. Phosphatidylcholine (PC) is an essential component contributing to formation of a hydrophobic mucus layer. For evaluation of PC in the pathogenesis of inflammatory bowel disease, the concentration and composition of PC in the rectal mucus of patients with ulcerative colitis was determined. Electrospray ionization (ESI) tandem mass spectrometry (MS/MS) allows quantification of PC species and enables analysis of crude extracts.
METHODS: Lipid extracts of material obtained by light scrapings of the intestinal lumen were analysed quantitatively by nanoESI MS/MS with synthetic internal PC and lysophosphatidylcholine (LPC) standards. PC and LPC species from rectoscopically acquired mucus aliquots of patients with ulcerative colitis were compared to Crohn disease and control subjects.
RESULTS: Patients with inactive ulcerative colitis showed significantly less PC and LPC (median 346 [IQR: 230-405] pmol total PC/mg dry weight) in rectal mucus compared to Crohn disease (median 126 [IQR: 465-1941] pmol total PC/mg dry weight) and control subjects (median 1285 [IQR: 850-1639] pmol total PC/mg dry weight) (P < 0.05). The molecular species of PC and LPC were not significantly different between the groups. The most abundant species were PC 16:0/18:1; PC 16:0/18:2; PC 18:0/18:1; PC 18:0/18:2; LPC 16:0; and LPC 18:0.
CONCLUSION: NanoESI MS/MS is a suitable tool for analysing and quantifying small amounts of PC in human mucus. Patients with ulcerative colitis have significant less PC in their intestinal mucus despite a comparable PC molecular species composition pattern. This suggests that a low amount of protective mucus PC is a characteristic feature in ulcerative colitis and explains an increased susceptibility to luminal contents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15513358     DOI: 10.1080/00365520410006233

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  56 in total

Review 1.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

Review 2.  Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?

Authors:  P R Gibson; J G Muir
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  In vivo analysis of mucosal lipids reveals histological disease activity in ulcerative colitis using endoscope-coupled Raman spectroscopy.

Authors:  Hao Ding; Andrew W Dupont; Shashideep Singhal; Larry D Scott; Sushovan Guha; Mamoun Younes; Xiaohong Bi
Journal:  Biomed Opt Express       Date:  2017-06-23       Impact factor: 3.732

4.  Prostaglandin E₂ and polyenylphosphatidylcholine: stiff competition for the fibrotic complications of inflammatory bowel disease?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Dig Dis Sci       Date:  2015-04-24       Impact factor: 3.199

5.  Protective effects of citicoline on TNBS-induced experimental colitis in rats.

Authors:  Rauf Onur Ek; Mukadder Serter; Kemal Ergin; Serpil Cecen; Cengiz Unsal; Yuksel Yildiz; Mehmet D Bilgin
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  [Microbiome and nutrition. The way to a future therapy for chronic inflammatory bowel diseases?].

Authors:  S Schreiber; S Nikolaus; P Rosenstiel
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

Review 7.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

8.  Zebrafish fat-free is required for intestinal lipid absorption and Golgi apparatus structure.

Authors:  Shiu-Ying Ho; Kristin Lorent; Michael Pack; Steven A Farber
Journal:  Cell Metab       Date:  2006-04       Impact factor: 27.287

9.  Intestinal lipid alterations occur prior to antibody-induced prostaglandin E2 production in a mouse model of ischemia/reperfusion.

Authors:  Byron L Sparkes; Emily E Archer Slone; Mary Roth; Ruth Welti; Sherry D Fleming
Journal:  Biochim Biophys Acta       Date:  2010-01-18

10.  An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.